Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,624.70
(
-1.36%
)
US TECH 100
23,664.80
(
-0.55%
)
Dow Jones
46,225.15
(
0.00%
)
Brent Oil
109.68
(
2.90%
)
Bitcoin
69,890.92
(
-1.89%
)
News Focus
News Focus
Post# of 257257
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122795
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: Rocky3 post# 113385

Wednesday, 01/26/2011 11:10:14 PM

Wednesday, January 26, 2011 11:10:14 PM

Post# of 257257

I have been using quarterly overhead at ~$20MM. I think it will be closer to $25MM by the end of '11.

Such a distinction is inconsequential in the overall scheme of things. In the unlikely (IMO) event that Teva gets FDA approval for Lovenox, MNTA will presumably adjust its operating costs to a level commensurate with lower revenues.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now